Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

NCT02126020 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No patients met eligibility criteria. The study has been closed.

Conditions

Stevens-Johnson Syndrome
Toxic Epidermal Necrolysis (Lyell) Syndrome
Mucous Membrane Pemphigoid

Interventions

DRUG: topical infliximab

Sponsor

James Chodosh, MD, MPH

Collaborators

[object Object]
[object Object]